Get the Stockscreener App
1.94
4.90%
-0.10
After Hours:
1.94
Pacific Biosciences Of California Inc stock is traded at $1.94, with a volume of 11.35M.
It is down -4.90% in the last 24 hours and down -20.16% over the past month.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
See More
Previous Close:
$2.04
Open:
$2.06
24h Volume:
11.35M
Relative Volume:
1.28
Market Cap:
$585.70M
Revenue:
$188.87M
Net Income/Loss:
$-400.38M
P/E Ratio:
-1.2933
EPS:
-1.5
Net Cash Flow:
$-260.90M
1W Performance:
+5.43%
1M Performance:
-20.16%
6M Performance:
+31.08%
1Y Performance:
-7.62%
1-Day Range:
$1.93
$2.12
1-Week Range:
$1.845
$2.22
52-Week Range:
$0.8511
$2.725
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Name
Pacific Biosciences Of California Inc
Sector
Industry
Phone
650-521-8000
Address
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.94 | 615.89M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
125.92 | 219.41B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
97.64 | 145.84B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
367.54 | 140.43B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
97.53 | 126.52B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
85.13 | 49.08B | 5.88B | 1.34B | 799.60M | 2.3489 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-24 | Downgrade | UBS | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-22-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-18-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-17-23 | Upgrade | UBS | Neutral → Buy |
| Oct-31-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jun-30-23 | Initiated | Goldman | Buy |
| May-10-23 | Initiated | Barclays | Equal Weight |
| Mar-31-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Feb-02-23 | Initiated | UBS | Neutral |
| Jan-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-21-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Neutral |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Sep-27-21 | Initiated | Canaccord Genuity | Buy |
| Feb-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-03-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-02-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-09-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-15-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-02-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-19-18 | Initiated | Cowen | Outperform |
| Nov-03-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-28-17 | Downgrade | CL King | Buy → Neutral |
| Nov-03-16 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-27-16 | Initiated | CL King | Buy |
| Apr-15-16 | Initiated | First Analysis Sec | Overweight |
| Feb-04-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-04-16 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-23-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-27-15 | Initiated | Cantor Fitzgerald | Buy |
| Feb-04-15 | Reiterated | Maxim Group | Buy |
| Sep-26-13 | Reiterated | Maxim Group | Buy |
| Jan-14-13 | Reiterated | Maxim Group | Buy |
View All
Pacific Biosciences Of California Inc Stock (PACB) Latest News
PacBio stock dips post latest launch to expand multiomics capabilities - MSN
Can Pacific Biosciences of California Inc. stock double in next 5 yearsDurability and Wear Notes & road comfort picks for daily use - ulpravda.ru
PacBio Stock Dips Post Latest Launch to Expand Multiomics Capabilities - sharewise.com
Can PacBio’s New CiFi Method Reshape PACB’s Innovation Story and Recurring Revenue Potential? - Yahoo Finance
Can Pacific Biosciences of California Inc. stock deliver consistent earnings growthOptions Play & Short-Term High Return Strategies - ulpravda.ru
What insider trading reveals about Pacific Biosciences of California Inc. stockTrade Exit Summary & Smart Investment Allocation Tips - ulpravda.ru
How Pacific Biosciences of California Inc. (P09) stock trades after rate cutsPortfolio Update Report & Reliable Entry Point Alerts - ulpravda.ru
Is Pacific Biosciences of California Inc. stock a defensive play in 20252025 Earnings Impact & Daily Growth Stock Investment Tips - ulpravda.ru
What technical charts say about Pacific Biosciences of California Inc. stockJuly 2025 Closing Moves & Free Weekly Watchlist of Top Performers - ulpravda.ru
PacBio introduces CiFi method for chromosome-scale genome assembly By Investing.com - Investing.com Canada
PacBio Introduces CiFi: A Breakthrough Method for Chromosome-Scale Genome Assemblies from Limited Sample Material - Quiver Quantitative
PacBio and UC Davis Researchers Introduce CiFi, a New Long-Read 3C Method That Enables Chromosome-Scale Assemblies from a Single SMRT Cell - MarketScreener
Will Pacific Biosciences of California Inc. (P09) stock justify high valuationFed Meeting & Expert Curated Trade Ideas - ulpravda.ru
Barclays analyst is bullish on Pacific Biosciences of California, Inc. (PACB) - MSN
3 Reasons to Sell PACB and 1 Stock to Buy Instead - Finviz
Pacific Biosciences of California (PACB) Gains As Market Dips: What You Should Know - sharewise.com
Here's Why You Should Add PacBio Stock to Your Portfolio - Yahoo Finance
PACB (Pacific Biosciences of California) Land And Improveme - GuruFocus
What analysts say about Pacific Biosciences of California Inc stockOptions Trading Strategies & Low Entry Cost Trading - earlytimes.in
Three Genomics Stocks Worth Tracking This Year - Nasdaq
We Think Pacific Biosciences of California (NASDAQ:PACB) Has A Fair Chunk Of Debt - simplywall.st
What drives Pacific Biosciences of California Inc P09 stock priceMarket Volatility Update & Missed Nvidia? Don’t Miss This One - earlytimes.in
Retail Surge: Will Pacific Biosciences of California Inc P09 stock rise with strong economyJuly 2025 Volume & Low Risk Entry Point Tips - moha.gov.vn
Stocks making big moves this week: PacBio, Crocs, FuelCell Energy, AMC Entertainment, and ON24 - The Globe and Mail
PacBio (PACB) Stock Is Up, What You Need To Know - Finviz
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap UpTime to Buy? - MarketBeat
What analysts say about Pacific Biosciences of California Inc P09 stockTechnical Resistance Breaks & Outstanding Capital Returns - earlytimes.in
Stocks making big moves yesterday: FuelCell Energy, Corcept, and PacBio - The Globe and Mail
Why Is PacBio (PACB) Stock Soaring Today - Finviz
Cathie Wood’s Strategic Move: ARK Investment Buys PacBio Shares - StocksToTrade
Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks - Benzinga
Pacific Biosciences of California (NASDAQ:PACB) Shares Up 7.1%Should You Buy? - MarketBeat
Cathie Wood’s ARK Investment Fuels PacBio Stock Surge - timothysykes.com
Barclays Analyst Is Bullish On Pacific Biosciences of California, Inc. (PACB) - Finviz
PacBio to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
How to watch PacBio’s J.P. Morgan Healthcare Conference webcast - Stock Titan
12 Best Genomics Stocks to Invest In - Insider Monkey
Pacific Biosciences of California (NASDAQ:PACB) Shares Down 5.1%What's Next? - MarketBeat
Cathie Wood’s ARK buys Weride, Pacific Biosciences stocks, sells Ibotta By Investing.com - Investing.com Nigeria
ARK Investment Acquires Additional Shares of PacBio (PACB) - GuruFocus
Cathie Wood’s ARK buys Weride, Pacific Biosciences stocks, sells Ibotta - Investing.com
ARK Investment Acquires Significant Stake in PacBio (PACB) - GuruFocus
Pacific Biosciences unveils gift campaign with coffee subscription giveaway - Traders Union
Pacific Biosciences of California Target of Unusually Large Options Trading (NASDAQ:PACB) - MarketBeat
Will Pacific Biosciences of California Inc. stock maintain dividend yieldJuly 2025 Decliners & Fast Moving Stock Watchlists - Улправда
Pacific Biosciences Of California Inc Stock (PACB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.31%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):